Caroline Fradette

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

High frequency in situ total alkalinity measurement for monitoring ocean alkalinity enhancement field trials.

High frequency in situ total alkalinity measurement for monitoring ocean alkalinity enhancement field trials.

Journal: Communications engineering

Published: June 09, 2025

Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies.

Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies.

Journal: Journal of Parkinson's disease

Published: February 20, 2025

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.

Journal: JAMA neurology

Published: November 04, 2024

Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy.

Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy.

Journal: Journal of clinical immunology

Published: July 25, 2024

Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.

Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.

Journal: Blood advances

Published: December 01, 2023

Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.

Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.

Journal: American journal of hematology

Published: November 27, 2023

Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.

Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.

Journal: Pediatric blood & cancer

Published: June 07, 2023

Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).

Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).

Journal: American journal of hematology

Published: January 10, 2023

Trial of Deferiprone in Parkinson's Disease.

Trial of Deferiprone in Parkinson's Disease.

Journal: The New England journal of medicine

Published: November 30, 2022

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.

Journal: Blood advances

Published: December 09, 2021

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.

Journal: Annals of hematology

Published: June 28, 2021

The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study.

The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study.

Journal: British journal of haematology

Published: June 16, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026